289 related articles for article (PubMed ID: 38053073)
21. Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.
Rosenson RS; Carlson DM; Kelly MT; Setze CM; Hirshberg B; Stolzenbach JC; Williams LA
Cardiovasc Drugs Ther; 2011 Feb; 25(1):47-57. PubMed ID: 21174145
[TBL] [Abstract][Full Text] [Related]
22. Prevalence and phenotypic distribution of dyslipidemia in type 1 diabetes mellitus: effect of glycemic control.
Pérez A; Wägner AM; Carreras G; Giménez G; Sánchez-Quesada JL; Rigla M; Gómez-Gerique JA; Pou JM; de Leiva A
Arch Intern Med; 2000 Oct; 160(18):2756-62. PubMed ID: 11025785
[TBL] [Abstract][Full Text] [Related]
23. The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease.
Pennell P; Leclercq B; Delahunty MI; Walters BA
Clin Nephrol; 2006 Nov; 66(5):336-47. PubMed ID: 17140163
[TBL] [Abstract][Full Text] [Related]
24. The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL.
Hanefeld M; Traylor L; Gao L; Landgraf W
Cardiovasc Diabetol; 2017 May; 16(1):66. PubMed ID: 28526014
[TBL] [Abstract][Full Text] [Related]
25. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
Morieri ML; Perrone V; Veronesi C; Degli Esposti L; Andretta M; Plebani M; Fadini GP; Vigili de Kreutzenberg S; Avogaro A
Cardiovasc Diabetol; 2021 Jul; 20(1):144. PubMed ID: 34271920
[TBL] [Abstract][Full Text] [Related]
26. Lipoprotein Ratios: Correlation With Glycated Hemoglobin (HbA1c) Among Thyroid Disorders' Patients.
Banerjee A; Lnu J; Lnu P; Bansal A
Cureus; 2024 Feb; 16(2):e54191. PubMed ID: 38496179
[TBL] [Abstract][Full Text] [Related]
27. Relationship between dyslipidaemia and glycaemic status in patients with Type 2 diabetes mellitus.
Thambiah SC; Samsudin IN; George E; Zahari Sham SY; Lee HM; Muhamad MA; Hussei Z; Mohd Noor N; Mohamad M
Malays J Pathol; 2016 Aug; 38(2):123-30. PubMed ID: 27568669
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of dyslipidemia, treatment rate and its control among patients with type 2 diabetes mellitus in Northwest China: a cross-sectional study.
Li J; Nie Z; Ge Z; Shi L; Gao B; Yang Y
Lipids Health Dis; 2022 Aug; 21(1):77. PubMed ID: 36002855
[TBL] [Abstract][Full Text] [Related]
29. Suboptimal control of lipid levels: results from the non-interventional Centralized Pan-Russian Survey of the Undertreatment of Hypercholesterolemia II (CEPHEUS II).
Boytsov S; Logunova N; Khomitskaya Y;
Cardiovasc Diabetol; 2017 Dec; 16(1):158. PubMed ID: 29246151
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of Dyslipidaemia Using an Algorithm of Lipid Profile Measures among Newly Diagnosed Type II Diabetes Mellitus Patients: A Cross-Sectional Study at Dormaa Presbyterian Hospital, Ghana.
Anto EO; Obirikorang C; Annani-Akollor ME; Adua E; Donkor S; Acheampong E; Asamoah EA
Medicina (Kaunas); 2019 Jul; 55(7):. PubMed ID: 31330902
[No Abstract] [Full Text] [Related]
31. Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus.
Fischer LT; Hochfellner DA; Knoll L; Pöttler T; Mader JK; Aberer F
Cardiovasc Diabetol; 2021 Apr; 20(1):89. PubMed ID: 33894772
[TBL] [Abstract][Full Text] [Related]
32. Long-term prognostic value of LDL-C, HDL-C, lp(a) and TG levels on cardiovascular disease incidence, by body weight status, dietary habits and lipid-lowering treatment: the ATTICA epidemiological cohort study (2002-2012).
Georgoulis M; Chrysohoou C; Georgousopoulou E; Damigou E; Skoumas I; Pitsavos C; Panagiotakos D
Lipids Health Dis; 2022 Dec; 21(1):141. PubMed ID: 36529737
[TBL] [Abstract][Full Text] [Related]
33. Correlation between Serum Lipid Profile with Anthropometric and Clinical Variables in Patients with Type 2 Diabetes Mellitus.
Biadgo B; Abebe SM; Baynes HW; Yesuf M; Alemu A; Abebe M
Ethiop J Health Sci; 2017 May; 27(3):215-226. PubMed ID: 29217920
[TBL] [Abstract][Full Text] [Related]
34. Relationship between very low low-density lipoprotein cholesterol concentrations not due to statin therapy and risk of type 2 diabetes: A US-based cross-sectional observational study using electronic health records.
Feng Q; Wei WQ; Chung CP; Levinson RT; Sundermann AC; Mosley JD; Bastarache L; Ferguson JF; Cox NJ; Roden DM; Denny JC; Linton MF; Edwards DRV; Stein CM
PLoS Med; 2018 Aug; 15(8):e1002642. PubMed ID: 30153257
[TBL] [Abstract][Full Text] [Related]
35. Cholesterol Paradox in Older People with Type 2 Diabetes Mellitus Regardless of Lipid-Lowering Drug Use: A Cross-Sectional Cohort Study.
Wang TY; Chang WL; Wei CY; Liu CH; Tzeng RC; Chiu PY
Nutrients; 2023 Jul; 15(14):. PubMed ID: 37513689
[TBL] [Abstract][Full Text] [Related]
36. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.
Brinton EA; Ballantyne CM; Bays HE; Kastelein JJ; Braeckman RA; Soni PN
Cardiovasc Diabetol; 2013 Jul; 12():100. PubMed ID: 23835245
[TBL] [Abstract][Full Text] [Related]
37. Comparison of on-Statin Lipid and Lipoprotein Levels for the Prediction of First Cardiovascular Event in Type 2 Diabetes Mellitus.
Kim JY; Choi J; Kim SG; Kim NH
Diabetes Metab J; 2023 Nov; 47(6):837-845. PubMed ID: 37915183
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006.
Tóth PP; Potter D; Ming EE
J Clin Lipidol; 2012; 6(4):325-30. PubMed ID: 22836069
[TBL] [Abstract][Full Text] [Related]
39. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study.
Erem C; Hacihasanoglu A; Deger O; Kocak M; Topbas M
Endocrine; 2008; 34(1-3):36-51. PubMed ID: 19003544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
